On September 6, 2023 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies, reported that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences (Press release, Curis, SEP 6, 2023, View Source [SID1234634940]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The H.C. Wainwright 25th Annual Global Investment Conference being held September 11 – 13, 2023. Presentation details are as follows:

Format: Company Presentation
Date: Tuesday, September 12, 2023
Time: 8:30am ET
The 2023 Cantor Global Healthcare Conference being held September 26 – 28, 2023. Presentation details are as follows:

Format: Panel Presentation
Date: Wednesday, September 27, 2023
Time: 9:10am ET
Webcasts will be available on the Curis website at www.curis.com in the ‘Investors’ section.